UP!

BCRX $70   View long term graphs

BioCryst Pharmaceuticals, Inc.
Type
Public (NASDAQ: BCRX)
Industry Healthcare
Founded 1986
Headquarters Durham, North Carolina, USA
Key people
Jon P. Stonehouse , President and Chief Executive Officer
Thomas Staab II, Chief Financial Officer
Products Biotechnology
Revenue IncreaseUS$26.3M (FY 2012)
Operating income
DecreaseUS$-33.9M (FY 2012)
Net income
DecreaseUS$-39.1M (FY 2012)
Total assets DecreaseUS$57.4M (FY 2012)
Total equity DecreaseUS$-0.4M (FY 2012)
Number of employees
37 (2013)
Website www.biocryst.com

BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Durham, North Carolina. The company focuses on orphan & autoimmune diseases, and antivirals. The company's most advanced drug candidate is the antiviral Peramivir, which is approved in Japan, Korea and China. It was authorized by the FDA for emergency use in the treatment of patients hospitalized with influenza during the 2009-10 influenza A virus subtype H1N1 pandemic.

The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.

BioCryst is a member of the Alliance for Biosecurity, a group of companies that work to develop vaccines and other measures that can be used in the case of a pandemic or bioterrorism attack.

News

BioCryst Pharmaceuticals, Inc. -1.86% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-03 Future report Set alerts
Q3 2020 2020-11-04 Future report Set alerts
Q2 2020 2020-08-06 -0.24 -0.24
Q1 2020 2020-05-06 -0.24 -0.24
Q4 2019 2020-03-05 -0.02 -0.02
Q3 2019 2019-11-06 -0.34 -0.34
Q2 2019 2019-08-06 -0.34 -0.34
Q1 2019 2019-05-08 -0.28 -0.28
Q4 2018 2019-03-04 -0.25 -0.25
Q3 2018 2018-11-06 -0.28 -0.28

Ratings

2016-07-06 Reiterated Rating FBR & Co Buy $6.00
2016-06-01 Upgrade Jefferies Group Hold to Buy $14.00
2016-05-09 Reiterated Rating HC Wainwright Buy $10.00
2016-03-09 Reiterated Rating FBR & Co. Outperform
2016-03-09 Reiterated Rating FBR & Co Outperform
2016-02-26 Reiterated Rating Noble Financial Buy $8.00
2016-02-25 Reiterated Rating HC Wainwright Buy $10.00
2016-02-11 Reiterated Rating HC Wainwright Buy $24.00 to $10.00
2016-02-10 Reiterated Rating Noble Financial Buy $21.00 to $8.00
2016-02-09 Downgrade Jefferies Buy to Hold $14.00 to $2.00
2016-02-09 Lower Price Target Rodman & Renshaw Buy $24.00 to $10.00
2016-02-09 Boost Price Target FBR & Co. Outperform $6.00 to $18.00
2016-02-09 Downgrade JPMorgan Chase & Co. Overweight to Neutral $16.00 to $5.00
2016-02-09 Downgrade Jefferies Group Buy to Hold $14.00 to $2.00
2016-02-08 Downgrade Needham & Company LLC Buy to Hold
2016-02-08 Downgrade Piper Jaffray Overweight to Neutral $15.00 to $5.00
2016-02-08 Downgrade Piper Jaffray Cos. Overweight to Neutral $15.00 to $5.00
2016-01-13 Lower Price Target JMP Securities $17.00 to $14.00
2016-01-12 Reiterated Rating FBR & Co. Outperform
2016-01-06 Upgrade Jefferies Group Hold to Buy $10.00 to $14.00
2015-11-11 Downgrade Bank of America Neutral to Underperform $12.00 to $10.00
2015-11-11 Downgrade Bank of America Corp. Neutral to Underperform $12.00 to $10.00
2015-11-10 Reiterated Rating Oppenheimer Market Perform
2015-11-10 Reiterated Rating Oppenheimer Holdings Inc. Market Perform
2015-11-06 Lower Price Target JPMorgan Chase & Co. Overweight $18.00 to $16.00
2015-10-15 Lower Price Target Jefferies Group Hold $12.00 to $10.00
2015-10-12 Reiterated Rating Noble Financial Buy
2015-10-09 Reiterated Rating FBR & Co. Outperform $18.00
2015-10-09 Downgrade Banc of America Sec Buy to Neutral
2015-10-09 Reiterated Rating HC Wainwright Buy $24.00
2015-10-09 Downgrade Bank of America Buy to Neutral $16.00 to $12.00
2015-10-08 Reiterated Rating Piper Jaffray Buy $18.00
2015-09-08 Initiated Coverage Jefferies Group Hold $12.00
2015-08-11 Reiterated Rating Piper Jaffray Overweight $18.00
2015-08-10 Reiterated Rating MLV & Co. Buy $15.00
2015-06-30 Upgrade Bank of America Neutral to Buy $12.00 to $19.00
2015-05-13 Reiterated Rating Oppenheimer Market Perform
2015-04-20 Initiated Coverage FBR & Co. Outperform $18.00
2015-04-20 Upgrade Bank of America Underperform to Neutral $8.00 to $12.00
2015-03-31 Set Price Target Needham & Company LLC Buy $15.00
2014-12-22 Set Price Target MLV & Co. Buy $15.00
2014-12-15 Reiterated Rating Noble Financial Buy
2014-12-09 Lower Price Target JPMorgan Chase & Co. Overweight $20.00 to $18.00
2014-12-04 Lower Price Target Bank of America Underperform $9.00 to $8.00
2014-08-08 Initiated Coverage JPMorgan Chase & Co. Overweight $20.00
2014-06-23 Upgrade Wells Fargo & Co. Market Perform to Outperform $19.00 to $17.00
2014-06-23 Upgrade Wells Fargo Market Perform to Outperform $19.00 to $17.00
2014-05-30 Boost Price Target HC Wainwright Buy $21.00 to $24.00
2014-05-28 Boost Price Target Roth Capital $18.00 to $20.00
2014-05-28 Reiterated Rating Bank of America Positive
2014-04-14 Initiated Coverage Brinson Patrick Outperform $15.00
2014-03-10 Initiated Coverage HC Wainwright Buy $21.00
2014-03-04 Reiterated MLV & Co Buy $9 to $15
2014-03-04 Boost Price Target MLV & Co. Buy $9.00 to $15.00
2014-02-28 Initiated Coverage Oppenheimer Market Perform
2014-02-20 Initiated Coverage Piper Jaffray Overweight $17.00
2014-02-20 Initiated Coverage Mizuho Buy $23.00
2014-02-18 Initiated Coverage Needham & Company LLC Buy $14.00
2014-01-28 Downgrade Bank of America Neutral to Underperform $9.81 to $9.00
2014-01-27 Downgrade Wells Fargo & Co. Outperform to Market Perform
2014-01-27 Downgrade Wells Fargo Outperform to Market Perform
2014-01-21 Initiated Coverage Roth Capital Buy $18.00
2014-01-13 Reiterated Rating JMP Securities Market Perform
2013-12-19 Reiterated MLV & Co Buy $6.50 to $9
2013-12-19 Boost Price Target MLV & Co. Buy $6.50 to $9.00
2013-11-12 Upgrade Bank of America Underperform to Neutral
2013-07-25 Reiterated MLV & Co Buy $3 to $6.50
2013-04-09 Upgrade MLV & Co Hold to Buy $3
2012-08-14 Downgrade WBB Securities Buy to Hold $8.50 to $4.40
2011-02-11 Reiterated JMP Securities Mkt Outperform $15 to $10
2010-09-29 Upgrade Rodman & Renshaw Mkt Perform to Mkt Outperform $7
2010-01-29 Initiated WBB Securities Buy $8.50
2009-10-13 Initiated JMP Securities Mkt Outperform $15
2008-01-25 Reiterated Caris & Company Average $8 to $4.50
2007-11-12 Reiterated Caris & Company Average $9.50 to $8
2007-09-20 Downgrade Caris & Company Above Average to Average $13 to $9.50
2007-09-17 Reiterated Caris & Company Above Average $10 to $13
2007-08-10 Reiterated Caris & Company Above Average $9.50 to $10
2016-07-06 Reiterated Rating FBR & Co Buy $6.00
2016-06-01 Upgrade Jefferies Group Hold to Buy $14.00
2016-05-09 Reiterated Rating HC Wainwright Buy $10.00
2016-03-09 Reiterated Rating FBR & Co. Outperform
2016-03-09 Reiterated Rating FBR & Co Outperform

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BAKER BROS. ADVISORS LP 13.13%  (9418390) ACAD / ALXN / AQXP / BCRX / GHDX / IDRA / INCY / MRTX / SGEN / XOMA /
Stonehouse Jon P President & CEO 0.91%  (655092) BCRX /
BAKER FELIX 0.20%  (145533) ACAD / ALXN / BCRX / GEVA / GHDX / MRTX / SGEN /
STAAB THOMAS R II Senior Vice President and CFO 0.19%  (137383) BCRX /
Cohen Fred E 0.17%  (119410) BCRX / CDNA / FPRX / GHDX / ROKA / TNDM / VCYT /
Babu Yarlagadda S VP Drug Discovery 0.15%  (108871) BCRX /
Barnes Alane P VP, General Counsel & Corp Sec 0.12%  (85768) BCRX /
Jensen Peder 0.08%  (60000) ACOR / BCRX / FPRX /
Hutson Nancy J 0.05%  (38147) BCRX / CBST / ENDP /
McCullough David VP 0.03%  (24124) BCRX /
INGRAM ROBERT ALEXANDER 0.03%  (18902) BCRX / CREE / EW / REGN / VRX /
Sheridan William P SR VP - CMO 0.03%  (18058) BCRX /
SANDERS CHARLES A 0.02%  (12971) BCRX / BIOD / LPDX /
LEE KENNETH B JR 0.01%  (10252) ARLZ / BCRX / POZN /
ABERCROMBIE GEORGE B 0.01%  (10000) BCRX / OCRX / THRX / ZIOP /
LOWREY ROBERT S Controller, PAO 0.01%  (9766) BCRX / MGT /
Powell Lynne Senior VP - CCO 0.01%  (8605) BCRX /

Comments